Associations with donor chimerism
| Characteristic . | Donor chimerism . | Pfrom Fisher exact test . | |
|---|---|---|---|
| Yes (%) . | No . | ||
| Diagnosis | |||
| Hematologic tumor | 9 (75.0) | 3 | .00015-150 |
| Solid tumor | 0 (0.0) | 13 | |
| Dose of T cell | |||
| 1 × 108 | 8 (57.1) | 6 | .035-150 |
| Other | 1 (9.1) | 10 | |
| Graft type | |||
| Allo cord | 0 (0.0) | 7 | .035-150 |
| Allo PB | 9 (50.0) | 9 | |
| Days to ANC more than 500 | |||
| Less than 5 | 0 (0.0) | 3 | .51 |
| 5 or more | 4 (36.4) | 7 | |
| Number of RBC transfusion | |||
| Less than 5 | 3 (20.0) | 12 | .09 |
| 5 or more | 6 (60.0) | 4 | |
| Number of platelet transfusion | |||
| Less than 5 | 3 (17.7) | 14 | .015-150 |
| 5 or more | 6 (75.0) | 2 | |
| Acute GVHD | |||
| Yes | 5 (83.3) | 1 | .015-150 |
| No | 4 (21.1) | 15 | |
| Prior myelotoxic therapy score5-151 | |||
| 0 | 0 (0.0) | 4 | .0015-150 |
| (Pvalues from Mantel-Haenszel χ2 test for trend) | |||
| 1 | 0 (0.0) | 2 | |
| 2 | 0 (0.0) | 2 | |
| 3 | 0 (0.0) | 1 | |
| 4 | 1 (33.3) | 2 | |
| 5 | 0 (0.0) | 1 | |
| 6 | 0 (0.0) | 1 | |
| 8 | 1 (50.0) | 1 | |
| 9 | 3 (75.0) | 1 | |
| 10 | 1 (100.0) | 0 | |
| 11 | 1 (100.0) | 0 | |
| 12 | 0 (0.0) | 1 | |
| 13 | 2 (100.0) | 0 | |
| Characteristic . | Donor chimerism . | Pfrom Fisher exact test . | |
|---|---|---|---|
| Yes (%) . | No . | ||
| Diagnosis | |||
| Hematologic tumor | 9 (75.0) | 3 | .00015-150 |
| Solid tumor | 0 (0.0) | 13 | |
| Dose of T cell | |||
| 1 × 108 | 8 (57.1) | 6 | .035-150 |
| Other | 1 (9.1) | 10 | |
| Graft type | |||
| Allo cord | 0 (0.0) | 7 | .035-150 |
| Allo PB | 9 (50.0) | 9 | |
| Days to ANC more than 500 | |||
| Less than 5 | 0 (0.0) | 3 | .51 |
| 5 or more | 4 (36.4) | 7 | |
| Number of RBC transfusion | |||
| Less than 5 | 3 (20.0) | 12 | .09 |
| 5 or more | 6 (60.0) | 4 | |
| Number of platelet transfusion | |||
| Less than 5 | 3 (17.7) | 14 | .015-150 |
| 5 or more | 6 (75.0) | 2 | |
| Acute GVHD | |||
| Yes | 5 (83.3) | 1 | .015-150 |
| No | 4 (21.1) | 15 | |
| Prior myelotoxic therapy score5-151 | |||
| 0 | 0 (0.0) | 4 | .0015-150 |
| (Pvalues from Mantel-Haenszel χ2 test for trend) | |||
| 1 | 0 (0.0) | 2 | |
| 2 | 0 (0.0) | 2 | |
| 3 | 0 (0.0) | 1 | |
| 4 | 1 (33.3) | 2 | |
| 5 | 0 (0.0) | 1 | |
| 6 | 0 (0.0) | 1 | |
| 8 | 1 (50.0) | 1 | |
| 9 | 3 (75.0) | 1 | |
| 10 | 1 (100.0) | 0 | |
| 11 | 1 (100.0) | 0 | |
| 12 | 0 (0.0) | 1 | |
| 13 | 2 (100.0) | 0 | |
Allo cord indicates allogeneic cord blood; allo PB, allogeneic peripheral blood.
Achieve significance level of .05.
“Score” indicates grading for previous myelotoxic therapy. Score = (no. of prior chemotherapy drugs) + 5 × (prior bone marrow transplantation), where “prior bone marrow transplantation” = 1 if patient had prior bone marrow transplantation, otherwise “prior bone marrow transplantation” = 0.